Carl Zeiss Meditec AG

Latest Results (02.10.2025):

Carl Zeiss Meditec AG reported strong financial performance in the first nine months of fiscal year 2024/25, achieving a revenue of €1,600.1 million, which represents a 7.6% increase compared to the previous year. The company's earnings before interest, taxes, and amortization (EBITA) also rose to €175.4 million, reflecting continued growth despite challenging market conditions.

Revenue Growth

Revenue increased by 7.6% to €1,600.1 million in the first nine months of fiscal year 2024/25, adjusted for currency effects up by 8.0%. This growth was driven by significant order intake, which rose by 23.3%, and steady performance across both the Ophthalmology and Microsurgery business units.

Strong Regional Performance

The EMEA region saw a revenue increase of 11.7% to €482.8 million, while the Americas region grew by 14.2% to €407.5 million. These gains were supported by robust market contributions from Germany, the UK, Scandinavia, and North America, despite a slight decline in the APAC region.

Enhanced EBITA

EBITA reached €175.4 million, up from €170.2 million in the prior year, resulting in an EBITA margin of 11.0%. This improvement was achieved despite negative currency effects and the introduction of US trade tariffs, highlighting the company's ability to maintain profitability.

Outlook for Fiscal Year

Carl Zeiss Meditec expects moderate revenue growth for the full fiscal year 2024/25, with EBITA margins anticipated to remain stable or slightly increase. The company plans to mitigate the impact of US trade tariffs through strategic pricing and continues to focus on accelerating device deliveries to meet fiscal targets.